Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
|Podcasts|May 23, 2023
Dr. Gange discusses data on the UroLift System for BPH
Author(s)Urology Times staff
The data were presented at the recent American Urological Association Annual Meeting.
Advertisement
In this episode, Steven Gange, MD, FACS, discusses notable data on the UroLift System for the treatment of patients with benign prostatic hyperplasia (BPH), which were presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Gange is a urologist at Summit Urology Group in Salt Lake City, Utah as well as an Associate Medical Director for Teleflex. He discusses the following abstracts:
- MP76-03: "Procedural Complications Associated with MIST and Invasive Surgery Compared to Disease Progression with Medical Therapy"
- PD41-06: "Pooled analysis of 330+ subjects treated with the Prostatic Urethral Lift (PUL) reveals undertreatment impacts durability"
- MP76-17: "Successful Outcomes in Acute Urinary Retention (AUR) Patients Treated with the Prostatic Urethral Lift (PUL) are Associated with Earlier Intervention"
Advertisement
Related to this article
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5